ArticleMedical oncology (Northwood, London, England)2023
Propionate-producing Veillonella parvula regulates the malignant properties of tumor cells of OSCC.
Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Systematic verification of saliva-based biosignatures for oral cancer via targeted metabolomics.Journal of food and drug analysis · 2026Article
- Shaping death: how the microbiome regulates tumour cell demise and therapy response.Cancer metastasis reviews · 2026Review
- The role ofFrontiers in oral health · 2026Review
- Article
- Spatial and temporal dynamic changes of oral microbiome in removable partial denture wearers: a longitudinal study using full-length 16S rRNA sequencing.Journal of oral microbiology · 2025Article
- Dissecting the intratumoral microbiome landscape in lung cancer.Frontiers in immunology · 2025Review
- Oral microbial signatures underlying recurrence via PI3K/AKT/mTOR pathway modulation in oral squamous cell carcinoma.Journal of oral microbiology · 2025Article
- Detecting and quantifying Veillonella by real-time quantitative PCR and droplet digital PCR.Applied microbiology and biotechnology · 2024Article
- Veillonella parvula as an anaerobic lactate-fermenting bacterium for inhibition of tumor growth and metastasis through tumor-specific colonization and decrease of tumor's lactate level.Scientific reports · 2024Article
- Roles of intralesional bacteria in the initiation and progression of oral squamous cell carcinoma.Cancer medicine · 2024Review
- Modulation of Gut Microbial Biomarkers and Metabolites in Cancer Management by Tea Compounds.International journal of molecular sciences · 2024Review
- gNOMO2: a comprehensive and modular pipeline for integrated multi-omics analyses of microbiomes.GigaScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Oral squamous cell carcinoma (OSCC), main head and neck squamous cell carcinomas (HNSCCs), remains a global health concern with unknown pathogenesis. Veillonella parvula NCTC11810 was observed to decrease in saliva microbiome of OSCC patients in this study and the aim was to detect the novel role of Veillonella parvula NCTC11810 in regulating the biological characteristics of OSCC through TROP2/PI3K/Akt pathway. Oral microbial community changes of OSCC patients were detected by 16S rDNA gene sequencing technology. CCK8 assay, Transwell assay, and Annexin V-FITC/PI staining were used for proliferation, invasion, and apoptosis analysis of OSCC cell lines. Expression of proteins were determined by Western blotting analysis. Veillonella parvula NCTC11810 showed decreased in saliva microbiome of TROP2 high-expressed OSCC patients. Culture supernatant of Veillonella parvula NCTC11810 promoted the apoptosis and inhibited the proliferation and invasion ability of HN6 cells, while sodium propionate (SP), the main metabolite of Veillonella parvula NCTC11810, played a similar role through the inhibition of TROP2/PI3K/Akt pathway. Studies above supported the proliferation-inhibiting, invasion-inhibiting, and apoptosis-promoting function of Veillonella parvula NCTC11810 in OSCC cells which provided new insights into oral microbiota and their metabolite as a therapeutic method for OSCC patients with TROP2 high expressing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.